bezafibrate has been researched along with Weight Gain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, XY; Yang, YJ; Zhu, XH | 1 |
| Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA | 1 |
2 other study(ies) available for bezafibrate and Weight Gain
| Article | Year |
|---|---|
The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Bezafibrate; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Risperidone; Schizophrenia; Weight Gain; Young Adult | 2019 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain | 2009 |